Wedbush Research Analysts Cut Earnings Estimates for Ardelyx

Key Points

• Wedbush analysts have cut their FY2025 earnings estimates for Ardelyx to ($0.29) per share, down from their previous forecast of ($0.28), while maintaining an "Outperform" rating and a price target of $14.00 for the stock.
• Ardelyx reported a net margin of -14.60% and a revenue of $97.66 million for the most recent quarter, exceeding analyst estimates of $82.69 million.
• Institutional investors currently own 58.92% of Ardelyx's stock, indicating strong interest from larger investment firms in the biopharmaceutical company.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities researchers at Wedbush decreased their FY2025 earnings estimates for shares of Ardelyx in a research report issued to clients and investors on Tuesday, October 14th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($0.29) per share for the year, down from their previous forecast of ($0.28). Wedbush has a "Outperform" rating and a $14.00 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's Q1 2026 earnings at ($0.04) EPS and FY2029 earnings at $0.99 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The firm had revenue of $97.66 million for the quarter, compared to analyst estimates of $82.69 million. During the same quarter in the previous year, the firm posted ($0.07) EPS. The business's revenue for the quarter was up 23.0% on a year-over-year basis.

ARDX has been the topic of a number of other reports. Piper Sandler increased their price target on shares of Ardelyx from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Ardelyx from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. HC Wainwright began coverage on shares of Ardelyx in a research note on Wednesday, June 18th. They set a "buy" rating and a $10.00 price target for the company. Raymond James Financial began coverage on shares of Ardelyx in a research note on Wednesday, September 3rd. They set a "strong-buy" rating and a $14.00 price target for the company. Finally, UBS Group set a $12.00 price target on shares of Ardelyx in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.70.

Ardelyx Stock Up 2.4%

Shares of NASDAQ ARDX opened at $5.13 on Thursday. The company has a quick ratio of 4.03, a current ratio of 4.30 and a debt-to-equity ratio of 1.44. Ardelyx has a 12-month low of $3.21 and a 12-month high of $6.78. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -22.30 and a beta of 0.67. The firm's 50-day simple moving average is $5.90 and its 200 day simple moving average is $4.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. DCF Advisers LLC acquired a new position in Ardelyx in the second quarter valued at about $39,000. Brighton Jones LLC bought a new position in Ardelyx in the second quarter valued at about $40,000. Cyndeo Wealth Partners LLC bought a new position in Ardelyx in the first quarter valued at about $49,000. Focus Partners Advisor Solutions LLC bought a new position in Ardelyx in the first quarter valued at about $56,000. Finally, State of Wyoming bought a new stake in shares of Ardelyx during the second quarter worth about $61,000. Institutional investors and hedge funds own 58.92% of the company's stock.

Insider Buying and Selling at Ardelyx

In other news, insider Elizabeth A. Grammer sold 5,841 shares of Ardelyx stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $5.93, for a total transaction of $34,637.13. Following the completion of the sale, the insider owned 305,890 shares of the company's stock, valued at approximately $1,813,927.70. This trade represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 45,687 shares of Ardelyx stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $5.93, for a total value of $270,923.91. Following the sale, the chief executive officer directly owned 1,502,250 shares of the company's stock, valued at $8,908,342.50. This represents a 2.95% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 165,551 shares of company stock worth $996,917. 4.80% of the stock is currently owned by corporate insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.